Introduction
Spinocerebellar Ataxia Type 1 (SCA1) is a late onset, autosomal dominant neurodegenerative disease caused by a polyglutamine (polyQ) expansion in the ataxin-1 protein. The average age of onset is within the fourth decade of life, although juvenile cases have been documented (Zoghbi et al., 1988) . Cell death in the cerebellar Purkinje cells and brain stem neurons is characteristic of SCA1 (Orr et al., 1993; Zoghbi and Orr, 1995) . Although not fully understood, mechanisms underlying neuropathy include an interplay between ataxin-1 and several proteins including 14-3-3 (Chen et al., 2003) , Rbm17 (Lim et al., 2008 ), Capicua (Lam et al., 2006 and Ataxin-1-like (Mizutani et al., 2005) .
The B05 transgenic mouse model of SCA1 expresses a polyQ expanded human ataxin-1 allele under control of the Purkinje cell specific promoter (Pcp2) (Burright et al., 1995) . Purkinje cell death occurs at approximately 24 weeks of age, with behavioral deficit onset at 5 weeks (Clark et al., 1997) . This implies that early symptoms reflect neuronal dysfunction but not overt cell loss, and raises the possibility that therapy can be initiated after disease onset. Work by Orr and colleagues using a doxycycline-inducible system investigated this possibility and found that if the disease gene was turned off after 6 weeks of expression, there was full reversibility. Notably, partial restoration of neuronal and behavioral deficits occurred if gene expression was turned off after 12 weeks (Zu et al., 2004) . Thus, there is a window of opportunity after disease onset to which therapies may have benefit.
Therapeutic intervention for SCA1 may involve small molecule approaches, such as those which have been investigated for SCA2 (Velazquez-Perez et al., 2011) , modulation of disease through overexpression of ataxin-1-like (Bowman et al., 2007) , or reducing expression of the disease allele through gene silencing (Alves et al., 2008; Gonzalez-Alegre et al., 2005) . In SCA1 knock-in mice (154Q) overexpressing an ataxin-1-like-transgenic allele, disease phenotypes improved (Lim et al., 2008) . The presumed mechanism for therapy based on ataxin-1-like overexpression is that ataxin-1-like, ataxin-1 and mutant, polyQ-expanded ataxin-1 all interact with Capicua through their AXH domain (de Chiara et al., 2003; Lam et al., 2006; Lim et al., 2008) . Interestingly, ataxin-1-like does not have a polyQ region but if overexpressed in vitro it can effectively compete away the mutant ataxin-1:Capicua interactions (Bowman et al., 2007) . A separate study showed that Rbm17 competes with Capicua to bind ataxin-1, with Rbm17 favoring interactions with mutant, polyQ-expanded ataxin-1, thus contributing to the toxic gain-of-function phenotype (Bowman et Neurobiology of Disease 56 (2013) 6-13 
